Agent
Number of individuals
Number of individuals with 4-fold seroconversions
GMT
of antibodies*
(95%CI)
Antibody titer increase rate
Number of individuals with protective
antibody titers (≥ 1:40)
No. (%) of Vol. (95%CI)**
Before vaccination
Day 21 after vaccination
No. (%) of Vol. (95%CI)**
Vaccine 3.75 µg HA
12
10
75.0
(46.8-91.1)
5.0
(5.0-5.0)
53.3
(22.3-127.4)
10.6
(4.4-25.4)
9
75.0
(46.8-91.1)
Vaccine 7.5 µg HA
12
12
75.0
(46.8-91.1)
5.0
(5.0-5.0)
160.0
(61.4-416.8)
32.0
(12.2-83.3)
9
75.0
(46.8-91.1)
Vaccine 15 µg HA
12
12
83.3
(55.2-95.3)
5.9
(4.5-7.8)
126.9
(59.4-271.3)
21.3
(10.4-43.6)
10
83.3
(55.2-95.3)
Placebo
18
0
0.00
(0.0-17.6)
5.83
(4.8-7.0)
6.3
(4.9-7.9)
1.0
(0.9-1.2)
0
0.0
(0.0-17.6)
*GMT of antibodies against pandemic influenza А/Н1N1pdm09
**95% CIs were computed using the Wilson score-based method
Table 4:
Immunogenic activity of the Refluvac
®
vaccine.
